U.S.-affiliated medical cannabis companies dominated Canadian Securities Exchange (CSE) fundraising in 2018, raising nearly $2 billion through 50 equity-related deals.
As of December 2018, 47% of the 124 cannabis-related companies trading on the CSE were based in the United States or had U.S. assets or interests.
Cannabis-related companies in the life sciences sector – which includes most of the marijuana-related companies listed on the stock exchange – accounted for 76% of all raises by CSE issuers for the year,
This post is from Marijuana Business Daily. We encourage our readers to continue reading the full article from the original source here.